Studies have shown that active fund managers routinely underperform the S&P500 index*​

Gain Therapeutics, Inc. (NASDAQ: GANX)

GANX Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
277.10%

GANX Stock Analysis

GANX PE Ratio:

GANX PEG Ratio: Not Available

GANX Forward EPS Growth (12 month): 0.00%

GANX PS Ratio:

GANX PSG Ratio: Not Available

GANX Forward Revenue Growth (12 month): 0.00%

GANX Articles

No data was found